SlideShare a Scribd company logo
1 of 10
Download to read offline
The new engl and jour nal of medicine
n engl j med  nejm.org 1
The authors’ full names, academic de-
grees, and affiliations are listed in the Ap-
pendix. Address reprint requests to Dr.
Jernigan at the Centers for Disease Con-
trol and Prevention, 1600 Clifton Rd.,
Mailstop A-31, Atlanta, GA 30333, or at
­jqj9@​­cdc​.­gov.
*A complete list of the investigators is in-
cluded in the Supplementary Appendix,
available at NEJM.org.
Ms. Arons and Ms. Hatfield contributed
equally to this article.
This article was published on April 24,
2020, at NEJM.org.
DOI: 10.1056/NEJMoa2008457
Copyright © 2020 Massachusetts Medical Society.
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can spread
rapidly within skilled nursing facilities. After identification of a case of Covid-19
in a skilled nursing facility, we assessed transmission and evaluated the adequacy
of symptom-based screening to identify infections in residents.
METHODS
We conducted two serial point-prevalence surveys, 1 week apart, in which assenting
residents of the facility underwent nasopharyngeal and oropharyngeal testing for
SARS-CoV-2, including real-time reverse-transcriptase polymerase chain reaction
(rRT-PCR), viral culture, and sequencing. Symptoms that had been present during
the preceding 14 days were recorded. Asymptomatic residents who tested positive
were reassessed 7 days later. Residents with SARS-CoV-2 infection were catego-
rized as symptomatic with typical symptoms (fever, cough, or shortness of breath),
symptomatic with only atypical symptoms, presymptomatic, or asymptomatic.
RESULTS
Twenty-three days after the first positive test result in a resident at this skilled nurs-
ing facility, 57 of 89 residents (64%) tested positive for SARS-CoV-2. Among 76 resi-
dents who participated in point-prevalence surveys, 48 (63%) tested positive. Of these
48 residents, 27 (56%) were asymptomatic at the time of testing; 24 subsequently
developed symptoms (median time to onset, 4 days). Samples from these 24 pre-
symptomatic residents had a median rRT-PCR cycle threshold value of 23.1, and
viable virus was recovered from 17 residents. As of April 3, of the 57 residents with
SARS-CoV-2 infection, 11 had been hospitalized (3 in the intensive care unit) and
15 had died (mortality, 26%). Of the 34 residents whose specimens were sequenced,
27 (79%) had sequences that fit into two clusters with a difference of one nucleotide.
CONCLUSIONS
Rapid and widespread transmission of SARS-CoV-2 was demonstrated in this skilled
nursing facility. More than half of residents with positive test results were asymp-
tomatic at the time of testing and most likely contributed to transmission. Infec-
tion-control strategies focused solely on symptomatic residents were not sufficient
to prevent transmission after SARS-CoV-2 introduction into this facility.
ABSTR ACT
Presymptomatic SARS-CoV-2 Infections and
Transmission in a Skilled Nursing Facility
M.M. Arons, K.M. Hatfield, S.C. Reddy, A. Kimball, A. James, J.R. Jacobs, J. Taylor,
K. Spicer, A.C. Bardossy, L.P. Oakley, S. Tanwar, J.W. Dyal, J. Harney, Z. Chisty,
J.M. Bell, M. Methner, P. Paul, C.M. Carlson, H.P. McLaughlin, N. Thornburg,
S. Tong, A. Tamin, Y. Tao, A. Uehara, J. Harcourt, S. Clark, C. Brostrom‑Smith,
L.C. Page, M. Kay, J. Lewis, P. Montgomery, N.D. Stone, T.A. Clark, M.A. Honein,
J.S. Duchin, and J.A. Jernigan, for the Public Health–Seattle and King County
and CDC COVID-19 Investigation Team*​​
Original Article
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med  nejm.org2
The new engl and jour nal of medicine
T
he first reported case of coronavi-
rus disease 2019 (Covid-19) in the United
States was diagnosed in a resident of Sno-
homish County, Washington, on January 20, 2020.1
In late February, an outbreak was identified in a
skilled nursing facility in neighboring King Coun-
ty; morbidity and mortality among residents were
high, straining the regional health care system.2,3
We report another outbreak of Covid-19 in a
separate skilled nursing facility in the same county.
In the course of this outbreak investigation, Pub-
lic Health–Seattle and King County (PHSKC) and
the Centers for Disease Control and Prevention
(CDC) identified residents with asymptomatic
SARS-CoV-2 infection, which prompted further
investigation. We performed serial point-preva-
lence surveys to assess the extent of transmission
and to evaluate the adequacy of symptom-based
screening of residents to identify infections. Ini-
tial findings of this investigation were previously
reported.4
Description of the Outbreak
On February 29, 2020, in response to increased
local awareness of Covid-19 in King County,
Washington, administrative leadership at Facility
A instituted enhanced infection-control measures.
Nursing staff assessed residents twice daily for
possible signs and symptoms of Covid-19, includ-
ing fever (oral or temporal temperature mea-
surement), cough, shortness of breath, and other
symptoms. Health care personnel were assessed
at the start of each shift with oral temperature
measurement and screening for symptoms, in-
cluding cough, shortness of breath, sore throat,
or any other respiratory symptoms.
On March 1, one member of the health care
staff tested positive for SARS-CoV-2 after having
worked in a single unit (Unit 1) while symptom-
atic on February 26, the first day of symptoms,
and on February 28. On March 5, the facility was
informed that a hospitalized resident of Unit 1
(in whom symptoms had developed on March 2
and testing was done on March 3) had been di-
agnosed with Covid-19. Subsequently, all visitors
were restricted and communal activities were can-
celed. PHSKC and the CDC initiated an outbreak
investigation, and on March 6, provided on-site
infection prevention and control recommenda-
tions, including the recommendation that all
health care staff entering symptomatic residents’
rooms wear eye protection, a gown, gloves, and
a face mask (N95 respirators were not routinely
available).5
On March 8, the CDC and PHSKC
offered testing to all residents in Unit 1; 13 of
15 residents present were tested for SARS-CoV-2
(2 residents declined). A total of 6 residents tested
positive; of these, 4 had symptoms (e.g., fever,
cough, shortness of breath, or sore throat) and
2 had been asymptomatic during the preceding
14 days. On March 9, the facility implemented
Covid-19 transmission-based precautions for all
residents of Unit 1, regardless of symptoms or
infection status.
Methods
Study Population
Facility A is a 116-bed skilled nursing facility di-
vided into four separate units with an equal mix of
short- and long-term residents in each unit. There
were 89 residents present at Facility A on March 3,
the date of the first positive test in a resident. Facil-
ity A provided a list of full-time health care person-
nel by occupation. Results of positive SARS-CoV-2
tests obtained during postmortem examination or
by outside health care providers during clinical
evaluation of symptomatic residents and staff were
provided to the CDC and PHSKC through March
26. All symptomatic health care personnel were
advised to be tested by their health care provider;
asymptomatic staff members were not tested as
part of this investigation.
Point-Prevalence Surveys
On two occasions, residents in the facility were
offered SARS-CoV-2 testing as part of a facility-
wide point-prevalence survey. The first survey was
performed for all assenting residents, including
those who had previously tested positive, on March
13 (10 days after the first resident had tested
positive for SARS-CoV-2). Nasopharyngeal and
oropharyngeal swabs were collected in accordance
with CDC guidelines.6
A second survey was con-
ducted 7 days later (March 19–20) for residents
who had had either a negative test result or a
positive result with atypical or no symptoms re-
ported in the first survey.
Symptom Assessment
On the day of point-prevalence surveys, a standard-
ized symptom-assessment form was completed by
nurses for each resident tested. Symptoms pres-
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med  nejm.org 3
Presymptomatic SARS-CoV-2 in a Nursing Facility
ent during the preceding 14 days were recorded on
the basis of interview and review of medical re-
cords. Asymptomatic residents with a positive test
result were reassessed for symptoms 7 days later.
For additional details on symptom assessment,
see the Supplementary Appendix, available with
the full text of this article at NEJM.org.
Residents were classified as symptomatic if
they had had at least one new or worsened typi-
cal or atypical symptom of Covid-19 in the pre-
ceding 14 days. Residents with subjective fever
or temperature greater than 100.0°F (37.8°C),
cough, or shortness of breath were classified as
symptomatic with typical symptoms.7
Residents
were classified as symptomatic with atypical symp-
toms if their symptoms included only chills, mal-
aise, increased confusion, rhinorrhea, nasal con-
gestion, sore throat, myalgia, dizziness, headache,
nausea, or diarrhea.
Asymptomatic residents were those who had
no symptoms or only stable chronic symptoms
(e.g., chronic cough without worsening). Pres-
ymptomatic residents were those who were as-
ymptomatic at the time of testing but developed
symptoms within 7 days after testing. Residents
who did not develop symptoms in the 7 days after
testing remained classified as asymptomatic.
Laboratory Testing
The Washington State Public Health Laboratory
performed one-step real-time reverse transcrip-
tase–polymerase chain reaction (rRT-PCR) on all
samples, using the SARS-CoV-2 CDC assay pro-
tocol; cycle threshold (Ct) values were reported
for two genetic markers: the N1 and N2 viral
nucleocapsid protein gene regions.8,9
Values below
40 cycles indicate a positive result for SARS-CoV-2.
All rRT-PCR–positive specimens from point-
prevalence surveys were shipped to the CDC for
viral culture using Vero-CCL-81 cells. Cells show-
ing cytopathic effect were used for SARS-CoV-2
rRT-PCR to confirm isolation and viral growth in
culture. Nucleic acid was extracted from rRT-PCR–
positive specimens and amplified for subsequent
sequencing (Oxford Nanopore MinION), with phy-
logenetic trees inferred with the neighbor-joining
method.10
Additional details on culture and se-
quencing methods are provided in the Supplemen-
tary Appendix.
Analyses
The daily proportions of residents with any known
positive test for SARS-CoV-2 (including those tested
as part of clinical management) were described
according to their unit in the facility. The daily
growth rate for the facility was estimated through
regression analysis, using the log-transformed
daily cumulative counts of all residents who were
positive for SARS-CoV-2 from March 3 through
March 20; doubling time was estimated by divid-
ing the natural logarithm of 2 by the growth
rate. Similarly, doubling time was estimated for
all residents of King County, using case count
data reported through the PHSKC Covid-19 data
dashboard.11
All analyses were completed with SAS soft-
ware, version 9.4 (SAS Institute). Data were
collected as part of public health response and
were deemed non–human subjects research by
the CDC.
Results
Residents
Of the 89 residents who lived in Facility A when
the first resident with confirmed Covid-19 was
tested, 57 (64%) had tested positive for SARS-
CoV-2 either during the point-prevalence surveys,
clinical evaluation, or postmortem examination
as of March 26. Seventy-six residents participat-
ed in the first point-prevalence survey on March
13 (Fig. 1). Of these 76 residents, 48 (63%) tested
positive in either the initial or subsequent point-
prevalence surveys. Demographic characteristics,
coexisting conditions, and symptoms of surveyed
residents were similar, regardless of test result
(Table 1).
Of the 48 residents who tested positive from
the surveys, 17 (35%) reported typical symptoms,
4 (8%) reported only atypical symptoms, and 27
(56%) reported no new symptoms or changes in
chronic symptoms at the time of testing (Table 1
and Table S1). Among the 27 residents classified
as asymptomatic, 15 reported no symptoms and
12 reported only stable chronic symptoms. Fif-
teen (56%) residents who were asymptomatic at
the time of testing had documented cognitive
impairment; similar proportions were reported in
symptomatic residents (Table S2).
In the 7 days after their positive test, 24 of the
27 asymptomatic residents (89%) had onset of
symptoms and were recategorized as presymp-
tomatic. The median time to symptom onset was
4 days (interquartile range, 3 to 5). The most com-
mon new symptoms were fever (71%), cough
(54%), and malaise (42%) (Table S3).
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med  nejm.org4
The new engl and jour nal of medicine
76WeretestedonMarch13
89ResidentsofFacilityAonMarch3
6Werehospitalized(alltestedpositiveforSARS-CoV-2inhospital)
1Wasdischargedhome
23Werepositive
1Whopreviouslytested
positivewasnegative
1Hadtypicalsymptoms
52Werenegative
49Wereretested
March19–20
12Wereasymp-
tomatic
9Hadtypical
symptoms
2Hadatypical
symptoms
15Wereasymp-
tomatic
7Hadtypical
symptoms
2Wereasymp-
tomatic
13Werepre-
symptomatic
2Hadatypical
symptoms
1Wasasymp-
tomatic
11Werepre-
symptomatic
24Werepositive25Werenegative
82ResidentsonMarch13
2Werehospitalizedbeforetesting(bothwerefoundtobepositive
duringhospitalization)
1Didnothavedataavailable
3Declinedtobetested(1foundtobepositivepostmortem)
3Leftfacilitybefore
March19
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med  nejm.org 5
Presymptomatic SARS-CoV-2 in a Nursing Facility
Cycle Threshold and Viral Culture
rRT-PCR Ct values for the N1 genetic markers for
47 residents ranged from 13.7 to 37.9; median Ct
values for the four symptom status groups were
similar (asymptomatic residents, 25.5; presymp-
tomatic residents, 23.1; residents with atypical
symptoms, 24.2; and residents with typical symp-
toms, 24.8) (Fig. 2). SARS-CoV-2 growth was iden-
tified from 31 of 46 rRT-PCR–positive specimens
(Fig. 2). Viral growth was observed for specimens
obtained from 10 of 16 residents with typical
symptoms, 3 of 4 with atypical symptoms, 17 of
Figure 1 (facing page). Residents in Facility A on
March 3 through Two Point-Prevalence Surveys.
Shown are all 89 residents who lived in skilled nursing
facility A from March 3, when the first resident tested
positive for SARS-CoV-2. By March 13, the date of the
first point-prevalence survey, 82 residents remained in
the facility, and 76 were tested. By the second point-
prevalence survey, 48 of the 76 residents tested in the
point-prevalence surveys had been identified as posi-
tive. Overall, 57 residents were positive as of March 26.
Cycle threshold values were available for 47 residents
who tested positive in the point-prevalence surveys on
March 13 and March 19–20.
Table 1. Demographic Characteristics and Reported Symptoms in Residents of Facility A at the Time of Testing.*
Characteristics SARS-CoV-2 Test Results
Positive†
(N = 48)
Negative‡
(N = 28)
Overall
Positive result during initial facility-wide cohort testing — no. (%) 23 (48) —
Mean age (±SD) — yr 78.6±9.5 73.8±11.5
Length of stay at Facility A <90 days before testing — no. (%) 23 (48) 14 (50)
Coexisting conditions — no. (%)
Any coexisting condition 47 (98) 28 (100)
Chronic lung disease 18 (38) 8 (29)
Diabetes 18 (38) 11 (39)
Cardiovascular disease 39 (81) 17 (61)
Cerebrovascular accident 19 (40) 8 (29)
Renal disease 18 (38) 9 (32)
Received hemodialysis 3 (6) 1 (4)
Cognitive impairment 28 (58) 13 (46)
Obesity 11 (23) 6 (21)
Symptoms during the past 14 days — no. (%)
In symptomatic residents§ 21 (44) 11 (39)
At least one typical Covid-19 symptom 17 (35) 8 (29)
Only atypical Covid-19 symptoms 4 (8) 3 (11)
In asymptomatic residents 27 (56) 18 (64)
No symptoms 15 (31) 14 (50)
Only stable, chronic symptoms 12 (25) 3 (11)
*	Results include all residents who were present in the facility on March 13 and assented to screening. Facility-wide co-
hort symptom screens and point-prevalence surveys were performed on March 13 and March 19–20, 2020.
†	Residents categorized as positive include those with at least one positive test from facility-wide point-prevalence sur-
veys on March 13 or March 19–20 and one resident who tested negative on March 13 but tested positive before March
13.
‡	Residents categorized as negative include 3 residents who had only one negative swab on March 13 and were not re-
tested.
§	Typical symptoms include fever, cough, and shortness of breath. Atypical symptoms include chills, malaise, sore throat,
increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea.
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med nejm.org6
The new engl and jour nal of medicine
24 who were presymptomatic, and 1 of 3 who
remained asymptomatic.
We observed no correlation between Ct values
and the number of days from the first evidence
of typical symptoms. Ct values consistent with a
high viral load were identified among residents
who tested positive before typical symptom on-
set (median Ct value among 26 observations,
24.0; interquartile range, 20.4 to 28.5) and those
who tested positive 7 or more days after typical
symptom onset (median Ct value among 8 obser-
vations, 25.0; interquartile range, 21.3 to 28.2)
(Fig. 3, and Fig. S1). Viable virus was isolated from
specimens collected 6 days before to 9 days after
the first evidence of typical symptoms.
Prevalence and Transmission in the Facility
We estimated the doubling time among residents
to be 3.4 days (95% confidence interval [CI], 2.5
to 5.3) (Table S4). The doubling time for the sur-
rounding King County was 5.5 days (95% CI, 4.8
to 6.7). As of April 3, a total of 11 of the 57 resi-
dents with SARS-CoV-2 infection identified by
March 26 had been admitted to the hospital (in-
cluding 3 in intensive care) and 15 had died (mor-
tality, 26%). The unit where presumed introduc-
tion of infection took place and where the first
resident with SARS-CoV-2 infection lived (Unit 1)
had the highest prevalence in the facility at the
end of the first point-prevalence survey. Although
other units identified SARS-CoV-2 infection in
residents later, their prevalence also continued to
increase (Fig. 4, and Fig. S4).
By the time of the first point-prevalence sur-
vey, 11 of 138 full-time staff members (8%) had
had a positive test for SARS-CoV-2. By March 26,
Figure 2. Cycle Threshold Values and Results of Viral Culture for Residents
with Positive SARS-CoV-2 Tests According to Their Symptom Status.
Shown are N1 target cycle threshold values and viral culture results for 47
residents’ first positive test for SARS-CoV-2 stratified by the resident’s
symptom status at the time of the test. One positive test was not assessed
for culture growth. Typical symptoms include fever, cough, and shortness
of breath; atypical symptoms include chills, malaise, increased confusion,
rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and
diarrhea.
10 15 20 25 30 35 40
Cycle Threshold Values for N1 Target
Positive culture Negative culture No culture
Typical Symptoms
(N=16)
Atypical Symptoms
(N=4)
Presymptomatic
(N=24)
Asymptomatic
(N=3)
Figure 3. Cycle Threshold Values Relative to First Evidence of Fever, Cough, or Shortness of Breath.
Shown are N1 target cycle threshold values and viral culture results for each resident’s positive tests for SARS-CoV-2
shown by day since the first evidence of fever, cough, or shortness of breath (N=55). Dates of onset of typical symp-
toms were known for 43 residents; 12 residents with two specimens that were positive for SARS-CoV-2 are also in-
cluded. One positive test was not assessed for culture growth. The relationship between the first test and the sec-
ond test for residents who had two positive tests is shown in Figure S2.
−9 −8 −7 −6 −5 −4 −3 −2 −1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Days from First Evidence of Fever, Cough, or Shortness of Breath
CycleThresholdValuesforN1Target
15
10
20
25
35
30
40
No culturePositive culture Negative culture
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med nejm.org 7
Presymptomatic SARS-CoV-2 in a Nursing Facility
a total of 55 of the 138 (40%) had reported symp-
toms, 51 (37%) had been tested, and 26 (19%) had
received a positive test result. Of the 26 staff mem-
bers with positive tests, 17 were nursing staff and
9 had occupations that provided services across
multiple units during their shift (therapists, en-
vironmental services, dietary services). No staff
members with Covid-19 were hospitalized.
Thirty-nine specimens from 34 residents were
sequenced. All sequences were identical or high-
ly similar to sequences reported in previous analy-
ses of Covid-19 cases in Washington (Fig. S3). Of
the 34 residents whose specimens were sequenced,
27 (79%) had sequences that fit into two clus-
ters with one nucleotide difference (Fig. S4 and
Table S5).
Discussion
Twenty-three days after identifying the first resi-
dent with SARS-CoV-2 infection, Facility A had a
64% prevalence of Covid-19 among residents, with
a case fatality rate of 26% despite early adoption of
infection-control measures. In addition, Covid-19
was diagnosed in 26 members of the staff (19%).
These findings are strikingly similar to descrip-
tions of the first Covid-19 outbreak in a U.S. skilled
nursing facility, which occurred in the same
county at nearly the same time.2
In the investiga-
tion reported here, more than half of the residents
with positive tests were asymptomatic at the time
of testing. Transmission from asymptomatic resi-
dents infected with SARS-CoV-2 most likely
contributed to the rapid and extensive spread of
infection to other residents and staff. Symptom-
based infection-control strategies were not suf-
ficient to prevent transmission after the intro-
duction of SARS-CoV-2 into this skilled nursing
facility.
Although we are unable to quantify the con-
tributions of asymptomatic and presymptomatic
residents to transmission of SARS-CoV-2 in this
facility, evidence suggests that these residents
had the potential for substantial viral shedding.
Figure 4. Timeline Showing Prevalence, Notable Events, and Implementation of Infection Prevention and Control Measures at Facility A.
Dashed lines indicate the prevalence of Covid-19 based on test results obtained during clinical evaluation of symptomatic residents be-
fore a unit-wide or facility-wide point-prevalence survey (PPS); the dotted line indicates the prevalence based on results from a unit-spe-
cific point-prevalence survey; and solid lines indicate the prevalence based on results from clinical evaluation and a facility-wide point-
prevalence survey. PPE denotes personal protective equipment.
PercentageofResidentsPositive
forSARS-CoV-2
100
80
90
70
60
40
30
10
50
20
0
Feb.25Feb.26Feb.27Feb.28Feb.29M
arch
1M
arch
2M
arch
3M
arch
4M
arch
5M
arch
6M
arch
7M
arch
8M
arch
9M
arch
10M
arch
11M
arch
12M
arch
13M
arch
14M
arch
15M
arch
16M
arch
17M
arch
18M
arch
19M
arch
20
Unit 1 Unit 2 Unit 3 Unit 4 Total
Suspected introduction
of SARS-CoV-2 from
symptomatic health care
personnel in Unit 1.
Temperature and
Covid-19 symptom
screening implemented
for all residents and
staff members.
Unit-wide testing
in Unit 1.
Covid-19–recommended
PPE implemented for
all of Unit 1.
Notification of PPS
test results.
Covid-19–recom-
mended PPE imple-
mented in all units.
Notification of first positive
test result in resident.
Covid-19–recommended
PPE implemented for
symptomatic residents.
Communal events canceled
and visitors restricted.
Initial facility-
wide point-
prevalence
survey. Follow-up
point-
prevalence
survey.
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med  nejm.org8
The new engl and jour nal of medicine
Ct values indicating large quantities of viral
RNA were identified, and viable SARS-CoV-2 was
isolated from specimens of asymptomatic and
presymptomatic residents. Evidence of transmis-
sion from presymptomatic persons has been
shown in epidemiologic investigations of SARS-
CoV-2.12-14
We estimated that the doubling time in this
facility was 3.4 days, which is faster than that of
the surrounding community, 5.5 days. The ac-
celerated doubling time was likely to have been
due to inadequately controlled intrafacility trans-
mission, which sequencing and spatiotemporal
data suggest was the primary driver of new in-
fections. Shedding of high viral titers from the
respiratory tract, including shedding before the
onset of symptoms, might have led to droplet and
possibly aerosol transmission. Residents and staff
members with undetected SARS-CoV-2 infection
are likely to have contributed to transmission
through interactions between and among resi-
dents and staff. The contribution of indirect con-
tact transmission in this outbreak is not known.
However, contaminated environmental surfaces
and shared medical devices could also have
played a role. Most of the early transmission ap-
peared to have occurred in Unit 1, where the ini-
tial introduction of SARS-CoV-2 took place, sev-
eral days before other units were involved. Early
recognition of initial SARS-CoV-2 introduction
combined with early interventions in all units
might prevent spread within a facility.
The CDC and PHSKC confirmed Covid-19
infection in 26 symptomatic staff members as-
sociated with this skilled nursing facility as of
March 26; these staff members most likely con-
tributed to intrafacility transmission. A concur-
rent study of King County health care personnel
with Covid-19 showed that 65% worked while
symptomatic and that 17% of symptomatic
health care personnel initially had mild, nonspe-
cific symptoms and no fever, cough, shortness
of breath, or sore throat.15
The potential for viral
shedding from staff members with SARS-CoV-2
infection during either the presymptomatic or
the mildly symptomatic phase of the illness re-
inforces current recommendations for expanded
symptom screening for health care personnel
and universal use of face masks for all health
care staff in long-term care facilities.5
Current interventions for preventing SARS-
CoV-2 transmission in health care settings rely
primarily on the presence of signs and symp-
toms to identify and isolate residents and staff
who might have Covid-19. The data presented
here suggest that sole reliance on symptom-
based strategies may not be effective to prevent
introduction of SARS-CoV-2 and further trans-
mission in skilled nursing facilities. Impaired
immune responses associated with aging and
the high prevalence of underlying conditions,
such as cognitive impairment and chronic cough,
make it difficult to recognize early signs and
symptoms of respiratory viral infections in this
population.16
Studies have shown that in the el-
derly, including those living in skilled nursing
facilities, influenza often manifests with few or
atypical symptoms, delaying diagnosis and con-
tributing to transmission.17,18
Furthermore, symp-
tom-based cohorting strategies could inadver-
tently increase the risk of SARS-CoV-2 exposure
for uninfected residents, given that typical symp-
toms were common in those who tested negative.
Our investigation demonstrated a poor cor-
relation between symptom onset and viral shed-
ding that was potentially due to the difficulty of
ascertaining precise dates of symptom onset or
to differences in viral shedding in this population.
Studies in other populations show that SARS-
CoV-2 shedding is highest early in the illness.19,20
Our investigation shows that some facility resi-
dents shed virus for more than 7 days after
symptom onset, a finding seen in some other
populations.21
These data support current rec-
ommendations preferring a test-based strategy
to discontinue transmission-based precautions for
residents of skilled nursing facilities.22
If a non–
test-based strategy is used, these data support
extending the duration of transmission-based
precautions.22
Because asymptomatic or presymptomatic
residents might play an important role in trans-
mission in this high-risk population, additional
prevention measures merit consideration, includ-
ing using testing to guide the use of transmis-
sion-based precautions, isolation, and cohort-
ing strategies. The ability to test large numbers of
residents and staff with rapid turn-around times
may expedite cohorting of residents and staff in
locations designated for the care of those with
SARS-CoV-2 infection either in different locations
within individual facilities or in separate facilities.
This investigation has several limitations.
First, challenges in symptom ascertainment may
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med  nejm.org 9
Presymptomatic SARS-CoV-2 in a Nursing Facility
have resulted in misclassification of symptom
grouping for some residents. However, multiple
sources of symptom data were used to minimize
such misclassification. The accuracy of symptom
ascertainment for this investigation is likely to
be equivalent to, if not exceed, symptom screen-
ing in most skilled nursing facilities, and thus,
these findings should be generalizable to this set-
ting. Second, because this analysis was conducted
among residents of a skilled nursing facility, it is
not known whether the findings apply to the
general population, including younger persons,
those without underlying medical conditions, or
similarly aged populations in the general com-
munity or in other long-term care settings. Third,
asymptomatic staff members were not tested;
therefore, we are unable to document their role in
transmission in this facility.
SARS-CoV-2 can spread rapidly after introduc-
tion into skilled nursing facilities, resulting in
substantial morbidity and mortality and increas-
ing the burden on regional health care systems.
Unrecognized asymptomatic and presymptomatic
infections most likely contribute to transmission
in these settings. During the current Covid-19
pandemic, skilled nursing facilities and all long-
term care facilities should take proactive steps to
prevent introduction of SARS-CoV-2. These steps
include restricting visitors and nonessential per-
sonnel from entering the building, requiring
universal use of face masks by all staff for source
control while in the facility, and implementing
strict screening of staff. Our data suggest that
symptom-based strategies for identifying residents
with SARS-CoV-2 are insufficient for preventing
transmission in skilled nursing facilities. Once
SARS-CoV-2 has been introduced, additional strate-
gies should be implemented to prevent further
transmission, including use of recommended per-
sonal protective equipment, when available, during
all resident care activities regardless of symptoms.5
Consideration should be given to test-based strate-
gies for identifying residents and staff with SARS-
CoV-2 infection for the purpose of excluding in-
fected staff and cohorting residents, either in
designated units within a facility or in a separate
facility designated for residents with Covid-19.
The findings and conclusion in this report are those of the
authors and do not necessarily represent the official position of
the Centers for Disease Control and Prevention.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
We thank the facility residents; the staff of Facility A for their
ongoing efforts to provide care in the face of these challenges;
staff at the local and state health departments responding to
this public health emergency; staff at the Washington State De-
partment of Health Public Health Laboratories; CDC staff at the
Emergency Operations Center; and members of the Covid-19
response teams at the local, state, and national levels for their
unwavering commitment in the face of this global public health
emergency.
Appendix
The authors’ full names and academic degrees are as follows: Melissa M. Arons, R.N., Kelly M. Hatfield, M.S.P.H., Sujan C. Reddy,
M.D., Anne Kimball, M.D., Allison James, Ph.D., Jesica R. Jacobs, Ph.D., Joanne Taylor, Ph.D., Kevin Spicer, M.D., Ana C. Bardossy,
M.D., Lisa P. Oakley, Ph.D., Sukarma Tanwar, M.Med., Jonathan W. Dyal, M.D., Josh Harney, M.S., Zeshan Chisty, M.P.H., Jeneita M.
Bell, M.D., Mark Methner, Ph.D., Prabasaj Paul, Ph.D., Christina M. Carlson, Ph.D., Heather P. McLaughlin, Ph.D., Natalie Thornburg,
Ph.D., Suxiang Tong, Ph.D., Azaibi Tamin, Ph.D., Ying Tao, Ph.D., Anna Uehara, Ph.D., Jennifer Harcourt, Ph.D., Shauna Clark, R.N.,
Claire Brostrom‑Smith, M.S.N., Libby C. Page, M.P.H., Meagan Kay, D.V.M., James Lewis, M.D., Patty Montgomery, M.P.H., Nimalie D.
Stone, M.D., Thomas A. Clark, M.D., Margaret A. Honein, Ph.D., Jeffrey S. Duchin, M.D., and John A. Jernigan, M.D.
The authors’ affiliations are as follows: the Centers for Disease Control and Prevention COVID-19 Emergency Response (M.M.A.,
K.M.H., S.C.R., A.K., A.J., J.R.J., J.T., K.S., A.C.B., L.P.O., S. Tanwar, J.W.D., J. Harney, Z.C., J.M.B., M.M., P.P., C.M.C., H.P.M.L.,
N.T., S. Tong, A.T., Y.T., A.U., J. Harcourt, N.D.S., T.A.C., M.A.H., J.A.J.), and the Epidemic Intelligence Service (M.M.A., A.K., A.J.,
J.T., A.C.B., L.P.O., S. Tanwar, J.W.D.) and the Laboratory Leadership Service (J.R.J., C.M.C.), Centers for Disease Control and Preven-
tion — all in Atlanta; and Public Health — Seattle  King County (S.C., C.B.-S., L.C.P., M.K., J.L., J.S.D.) and the University of Wash-
ington, Department of Medicine (J.S.D.), Seattle, the Washington State Public Health Laboratory, Shoreline (J.S.D.), and the Washington
State Department of Health, Tumwater (P.M.) — all in Washington.
References
1.	 Holshue ML, DeBolt C, Lindquist S,
et al. First case of 2019 novel coronavirus
in the United States. N Engl J Med 2020;​
382:​929-36.
2.	 McMichael TM, Currie DW, Clark S, et
al. Epidemiology of Covid-19 in a long-
term care facility in King County, Wash-
ington. N Engl J Med. DOI:​10.1056/
NEJMoa2005412.
3.	 McMichael TM, Clark S, Pogosjans S,
et al. COVID-19 in a long-term care facil-
ity — King County, Washington, February
27–March 9, 2020. MMWR Morb Mortal
Wkly Rep 2020;​69:​339-42.
4.	 Kimball A, Hatfield KM, Arons M, et al.
Asymptomatic and presymptomatic SARS-
CoV-2 infections in residents of a long-term
care skilled nursing facility — King County,
Washington, March 2020. MMWR Morb
Mortal Wkly Rep 2020;​69:​377-81.
5.	 Centers for Disease Control and Pre-
vention. Preparing for COVID-19: long-
term care facilities, nursing homes. 2020
(https://www​.cdc​.gov/​coronavirus/​2019
​-­ncov/​healthcare​-­facilities/​prevent​-­spread​
-­in​-­long​-­term​-­care​-­facilities​.html).
6.	 Centers for Disease Control and Pre-
vention. Interim guidelines for collecting,
handling, and testing clinical specimens
from persons for coronavirus disease 2019
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.
n engl j med  nejm.org10
The new engl and jour nal of medicine
(COVID-19). 2020 (https://www​.cdc​.gov/​
coronavirus/​2019​-­ncov/​lab/​guidelines​
-­clinical​-­specimens​.html).
7.	 Centers for Disease Control and Pre-
vention. Symptoms. Coronavirus 2019
(COVID-19). 2020 (https://www​.cdc​.gov/​
coronavirus/​2019​-­ncov/​symptoms​
-­testing/​symptoms​.html).
8.	 Centers for Disease Control and Pre-
vention. Real-time RT-PCR panel for detec-
tion 2019-novel coronavirus. 2020 (https://
www​.cdc​.gov/​coronavirus/​2019​-­ncov/​
downloads/​rt​-­pcr​-­panel​-­for​-­detection​
-­instructions​.pdf).
9.	 Centers for Disease Control and Pre-
vention. 2019-Novel coronavirus (2019-
nCoV) real-time rRT-PCR panel primers
and probes. 2020 (https://www​.cdc​.gov/​
coronavirus/​2019​-­ncov/​downloads/​rt​-­pcr​
-­panel​-­primer​-­probes​.pdf).
10.	Kumar S, Stecher G, Li M, Knyaz C,
Tamura K. MEGA X: molecular evolu-
tionary genetics analysis across comput-
ing platforms. Mol Biol Evol 2018;​35:​
1547-9.
11.	Public Health — Seattle and King
County. COVID-19 data dashboard: King
County COVID-19 outbreak summary
(https://kingcounty​.gov/​depts/​health/​
communicable​-­diseases/​disease​-­control/​
novel​-­coronavirus/​data​-­dashboard​
.aspx).
12.	 Wei WE, Li Z, Chiew CJ, Yong SE, Toh
MP, Lee VJ. Presymptomatic transmission
of SARS-CoV-2 — Singapore, January 23–
March 16, 2020. MMWR Morb Mortal
Wkly Rep 2020;​69:​411-5.
13.	 Tong Z-D, Tang A, Li K-F, et al. Poten-
tial presymptomatic transmission of
SARS-CoV-2, Zhejiang Province, China,
2020. Emerg Infect Dis 2020;​26:​1052-4.
14.	Qian G, Yang N, Ma AHY, et al. A
COVID-19 transmission within a family
cluster by presymptomatic infectors in
China. Clin Infect Dis 2020 March 23
(Epub ahead of print).
15.	Chow EJ, Schwartz NG, Tobolowsky
FA, et al. Symptom screening at illness
onset of health care personnel with SARS-
CoV-2 infection in King County, Washing-
ton. JAMA 2020 April 17 (Epub ahead of
print).
16.	Aw D, Silva AB, Palmer DB. Immu-
nosenescence: emerging challenges for
an ageing population. Immunology 2007;​
120:​435-46.
17.	 Lam P-P, Coleman BL, Green K, et al.
Predictors of influenza among older
adults in the emergency department. BMC
Infect Dis 2016;​16:​615.
18.	Sayers G, Igoe D, Carr M, et al. High
morbidity and mortality associated with
an outbreak of influenza A(H3N2) in a
psycho-geriatric facility. Epidemiol Infect
2013;​141:​357-65.
19.	 Zou L, Ruan F, Huang M, et al. SARS-
CoV-2 viral load in upper respiratory spec-
imens of infected patients. N Engl J Med
2020;​382:​1177-9.
20.	To KK-W, Tsang OT-Y, Leung W-S, et
al. Temporal profiles of viral load in pos-
terior oropharyngeal saliva samples and
serum antibody responses during infec-
tion by SARS-CoV-2: an observational co-
hort study. Lancet Infect Dis 2020 March
23 (Epub ahead of print).
21.	Young BE, Ong SWX, Kalimuddin S,
et al. Epidemiologic features and clinical
course of patients infected with SARS-
CoV-2 in Singapore. JAMA 2020 March 03
(Epub ahead of print).
22.	Centers for Disease Control and Pre-
vention. Discontinuation of transmission-
based precautions and disposition of pa-
tients with COVID-19 in healthcare
settings (interim guidance). 2020 (https://
www​.cdc​.gov/​coronavirus/​2019​-­ncov/​hcp/​
disposition​-­hospitalized​-­patients​.html).
Copyright © 2020 Massachusetts Medical Society.
The New England Journal of Medicine
Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.

More Related Content

What's hot

Respiratory virus shedding in exhaled breath and efficacy of face masks
Respiratory virus shedding in exhaled breath and efficacy of face masksRespiratory virus shedding in exhaled breath and efficacy of face masks
Respiratory virus shedding in exhaled breath and efficacy of face masksValentina Corona
 
Clinical course and risk factors for mortality of adult inpatients with covid...
Clinical course and risk factors for mortality of adult inpatients with covid...Clinical course and risk factors for mortality of adult inpatients with covid...
Clinical course and risk factors for mortality of adult inpatients with covid...BARRY STANLEY 2 fasd
 
COVID-19: in gastroenterology a clinical perspective
COVID-19: in gastroenterology a clinical perspectiveCOVID-19: in gastroenterology a clinical perspective
COVID-19: in gastroenterology a clinical perspectiveValentina Corona
 
Caring for the critical patient
Caring for the critical patientCaring for the critical patient
Caring for the critical patientValentina Corona
 
Jamainternal Internal Medicine
Jamainternal Internal MedicineJamainternal Internal Medicine
Jamainternal Internal MedicineValentina Corona
 
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian Perspective
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian PerspectiveOperational Planning of Hospitals towards COVID 19 Pandemic- Indian Perspective
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian PerspectiveLallu Joseph
 
PCR Assay Turned Positive in 25 Discharged COVID-19 Patients
PCR Assay Turned Positive in 25 Discharged COVID-19 PatientsPCR Assay Turned Positive in 25 Discharged COVID-19 Patients
PCR Assay Turned Positive in 25 Discharged COVID-19 PatientsValentina Corona
 
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in SingaporeStepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in SingaporeValentina Corona
 
Minimally invasive surgery and the novel coronavirus outbreak lessons learne...
Minimally invasive surgery and the novel coronavirus outbreak  lessons learne...Minimally invasive surgery and the novel coronavirus outbreak  lessons learne...
Minimally invasive surgery and the novel coronavirus outbreak lessons learne...Valentina Corona
 
Caring for patients with cancer in the COVID-19 era
Caring for patients with cancer in the COVID-19 eraCaring for patients with cancer in the COVID-19 era
Caring for patients with cancer in the COVID-19 eraValentina Corona
 
Virtually Perfect? Telemedicine for Covid-19
Virtually Perfect? Telemedicine for Covid-19Virtually Perfect? Telemedicine for Covid-19
Virtually Perfect? Telemedicine for Covid-19Valentina Corona
 
Covid-19 Navigating the Uncharted
Covid-19 Navigating the UnchartedCovid-19 Navigating the Uncharted
Covid-19 Navigating the UnchartedValentina Corona
 
Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...Valentina Corona
 
NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19
NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19
NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19PARUL UNIVERSITY
 
The Shifting Landscape of Genitourinary Oncology During the Covid-19 Pandemi...
The Shifting Landscape of Genitourinary Oncology  During the Covid-19 Pandemi...The Shifting Landscape of Genitourinary Oncology  During the Covid-19 Pandemi...
The Shifting Landscape of Genitourinary Oncology During the Covid-19 Pandemi...Valentina Corona
 
COVID 19- Basics beyond Basics by Dr. Brij Teli
COVID 19- Basics beyond Basics by Dr. Brij Teli COVID 19- Basics beyond Basics by Dr. Brij Teli
COVID 19- Basics beyond Basics by Dr. Brij Teli doc2rock
 

What's hot (20)

Respiratory virus shedding in exhaled breath and efficacy of face masks
Respiratory virus shedding in exhaled breath and efficacy of face masksRespiratory virus shedding in exhaled breath and efficacy of face masks
Respiratory virus shedding in exhaled breath and efficacy of face masks
 
Clinical course and risk factors for mortality of adult inpatients with covid...
Clinical course and risk factors for mortality of adult inpatients with covid...Clinical course and risk factors for mortality of adult inpatients with covid...
Clinical course and risk factors for mortality of adult inpatients with covid...
 
COVID-19: in gastroenterology a clinical perspective
COVID-19: in gastroenterology a clinical perspectiveCOVID-19: in gastroenterology a clinical perspective
COVID-19: in gastroenterology a clinical perspective
 
Caring for the critical patient
Caring for the critical patientCaring for the critical patient
Caring for the critical patient
 
Jamainternal Internal Medicine
Jamainternal Internal MedicineJamainternal Internal Medicine
Jamainternal Internal Medicine
 
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian Perspective
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian PerspectiveOperational Planning of Hospitals towards COVID 19 Pandemic- Indian Perspective
Operational Planning of Hospitals towards COVID 19 Pandemic- Indian Perspective
 
PCR Assay Turned Positive in 25 Discharged COVID-19 Patients
PCR Assay Turned Positive in 25 Discharged COVID-19 PatientsPCR Assay Turned Positive in 25 Discharged COVID-19 Patients
PCR Assay Turned Positive in 25 Discharged COVID-19 Patients
 
Covid 19
Covid 19Covid 19
Covid 19
 
Coronavirus
CoronavirusCoronavirus
Coronavirus
 
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in SingaporeStepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
 
Minimally invasive surgery and the novel coronavirus outbreak lessons learne...
Minimally invasive surgery and the novel coronavirus outbreak  lessons learne...Minimally invasive surgery and the novel coronavirus outbreak  lessons learne...
Minimally invasive surgery and the novel coronavirus outbreak lessons learne...
 
Caring for patients with cancer in the COVID-19 era
Caring for patients with cancer in the COVID-19 eraCaring for patients with cancer in the COVID-19 era
Caring for patients with cancer in the COVID-19 era
 
Virtually Perfect? Telemedicine for Covid-19
Virtually Perfect? Telemedicine for Covid-19Virtually Perfect? Telemedicine for Covid-19
Virtually Perfect? Telemedicine for Covid-19
 
Covid-19 Navigating the Uncharted
Covid-19 Navigating the UnchartedCovid-19 Navigating the Uncharted
Covid-19 Navigating the Uncharted
 
Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...Clinical features od severe pediatric patients with coronavirus disease 2019 ...
Clinical features od severe pediatric patients with coronavirus disease 2019 ...
 
Covid 19 & infertility
Covid 19 & infertilityCovid 19 & infertility
Covid 19 & infertility
 
NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19
NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19
NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19
 
Facing Covid-19 in Italy
Facing Covid-19 in ItalyFacing Covid-19 in Italy
Facing Covid-19 in Italy
 
The Shifting Landscape of Genitourinary Oncology During the Covid-19 Pandemi...
The Shifting Landscape of Genitourinary Oncology  During the Covid-19 Pandemi...The Shifting Landscape of Genitourinary Oncology  During the Covid-19 Pandemi...
The Shifting Landscape of Genitourinary Oncology During the Covid-19 Pandemi...
 
COVID 19- Basics beyond Basics by Dr. Brij Teli
COVID 19- Basics beyond Basics by Dr. Brij Teli COVID 19- Basics beyond Basics by Dr. Brij Teli
COVID 19- Basics beyond Basics by Dr. Brij Teli
 

Similar to Presynmptoms SARS-Cov-2 Infection and Transmission in Skilled Nursing Facility

Epidemiology of Covid-19 in a long-Term Care Facility in King County, Washington
Epidemiology of Covid-19 in a long-Term Care Facility in King County, WashingtonEpidemiology of Covid-19 in a long-Term Care Facility in King County, Washington
Epidemiology of Covid-19 in a long-Term Care Facility in King County, WashingtonValentina Corona
 
Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...
Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...
Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...MelendiNavarro
 
Hospital outbreak of middle east respiratory syndrome
Hospital outbreak of middle east respiratory syndromeHospital outbreak of middle east respiratory syndrome
Hospital outbreak of middle east respiratory syndromeDee Evardone
 
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Valentina Corona
 
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...JohnJulie1
 
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...suppubs1pubs1
 
Application of ordinal logistic=China.pdf
Application of ordinal logistic=China.pdfApplication of ordinal logistic=China.pdf
Application of ordinal logistic=China.pdfHenokBuno
 
Farmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores Malpartida
Farmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores MalpartidaFarmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores Malpartida
Farmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores MalpartidaFreddy Flores Malpartida
 
The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...
The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...
The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...asclepiuspdfs
 
1 jmv.27253.pdf
1 jmv.27253.pdf1 jmv.27253.pdf
1 jmv.27253.pdfGizaw10
 
Coronavirus Disease (COVID)-19 Outbeak
Coronavirus Disease (COVID)-19 OutbeakCoronavirus Disease (COVID)-19 Outbeak
Coronavirus Disease (COVID)-19 OutbeakTahseen Siddiqui
 
Jama sanders covid-19
Jama sanders covid-19Jama sanders covid-19
Jama sanders covid-19gisa_legal
 
Clinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 HighlightsClinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 HighlightsKumaraguru Veerasamy
 
Covid 19-book
Covid 19-bookCovid 19-book
Covid 19-bookimranndj
 
To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...
To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...
To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...YogeshIJTSRD
 

Similar to Presynmptoms SARS-Cov-2 Infection and Transmission in Skilled Nursing Facility (20)

Epidemiology of Covid-19 in a long-Term Care Facility in King County, Washington
Epidemiology of Covid-19 in a long-Term Care Facility in King County, WashingtonEpidemiology of Covid-19 in a long-Term Care Facility in King County, Washington
Epidemiology of Covid-19 in a long-Term Care Facility in King County, Washington
 
Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...
Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...
Factores de riesgo para reingreso temprano despues de hospitalizacion por cov...
 
Hospital outbreak of middle east respiratory syndrome
Hospital outbreak of middle east respiratory syndromeHospital outbreak of middle east respiratory syndrome
Hospital outbreak of middle east respiratory syndrome
 
Nejmoa
NejmoaNejmoa
Nejmoa
 
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020
 
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
 
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...
 
Application of ordinal logistic=China.pdf
Application of ordinal logistic=China.pdfApplication of ordinal logistic=China.pdf
Application of ordinal logistic=China.pdf
 
doi: 10.1101/2021.05.28.21258012
doi: 10.1101/2021.05.28.21258012doi: 10.1101/2021.05.28.21258012
doi: 10.1101/2021.05.28.21258012
 
Review article
Review articleReview article
Review article
 
Farmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores Malpartida
Farmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores MalpartidaFarmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores Malpartida
Farmacologia COVID Jama sanders 2020_rv_200005 Dr. Freddy Flores Malpartida
 
Jama sanders 2020 tto
Jama sanders 2020 ttoJama sanders 2020 tto
Jama sanders 2020 tto
 
Covid 19-ppt
Covid 19-pptCovid 19-ppt
Covid 19-ppt
 
The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...
The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...
The Gibraltar COVID-19 Cohort: Determining the True Incidence and Severity Ra...
 
1 jmv.27253.pdf
1 jmv.27253.pdf1 jmv.27253.pdf
1 jmv.27253.pdf
 
Coronavirus Disease (COVID)-19 Outbeak
Coronavirus Disease (COVID)-19 OutbeakCoronavirus Disease (COVID)-19 Outbeak
Coronavirus Disease (COVID)-19 Outbeak
 
Jama sanders covid-19
Jama sanders covid-19Jama sanders covid-19
Jama sanders covid-19
 
Clinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 HighlightsClinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 Highlights
 
Covid 19-book
Covid 19-bookCovid 19-book
Covid 19-book
 
To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...
To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...
To Assess the Severity and Mortality among Covid 19 Patients after Having Vac...
 

More from Valentina Corona

Progetto strategico SIU Oltre
Progetto strategico SIU OltreProgetto strategico SIU Oltre
Progetto strategico SIU OltreValentina Corona
 
Telehealth in Urology: A Systematic Review of the Literature.
Telehealth in Urology: A Systematic Review of the Literature.Telehealth in Urology: A Systematic Review of the Literature.
Telehealth in Urology: A Systematic Review of the Literature.Valentina Corona
 
Remdesivir for the Treatment of Covid-19
Remdesivir for the Treatment of Covid-19Remdesivir for the Treatment of Covid-19
Remdesivir for the Treatment of Covid-19Valentina Corona
 
Avoidng disruption of timely surgical management of genitourinary cancers ...
Avoidng disruption of timely surgical management of genitourinary cancers ...Avoidng disruption of timely surgical management of genitourinary cancers ...
Avoidng disruption of timely surgical management of genitourinary cancers ...Valentina Corona
 
Avoiding disruption of surgical treatment of genitourinary cancers...
Avoiding disruption of surgical treatment of genitourinary cancers...Avoiding disruption of surgical treatment of genitourinary cancers...
Avoiding disruption of surgical treatment of genitourinary cancers...Valentina Corona
 
A systematic review on COVID-1: urological manifestations...
A systematic review on COVID-1: urological manifestations...A systematic review on COVID-1: urological manifestations...
A systematic review on COVID-1: urological manifestations...Valentina Corona
 
Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...
Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...
Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...Valentina Corona
 
Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...
Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...
Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...Valentina Corona
 
A Global Survey on the Impact of COVID-19 on Urological Services
A Global Survey on the Impact of COVID-19 on Urological ServicesA Global Survey on the Impact of COVID-19 on Urological Services
A Global Survey on the Impact of COVID-19 on Urological ServicesValentina Corona
 
Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...Valentina Corona
 
Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...Valentina Corona
 
Androgen-deprivation therapies for prostate cancer and risk of infection by S...
Androgen-deprivation therapies for prostate cancer and risk of infection by S...Androgen-deprivation therapies for prostate cancer and risk of infection by S...
Androgen-deprivation therapies for prostate cancer and risk of infection by S...Valentina Corona
 
Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces
Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on SurfacesSimulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces
Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on SurfacesValentina Corona
 
Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...
Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...
Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...Valentina Corona
 
Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?
Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?
Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?Valentina Corona
 
Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19
Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19
Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19Valentina Corona
 
Assessment of Deaths from Covid 19 and from Seasonal Influenza
Assessment of Deaths from Covid 19 and from Seasonal Influenza Assessment of Deaths from Covid 19 and from Seasonal Influenza
Assessment of Deaths from Covid 19 and from Seasonal Influenza Valentina Corona
 
Protocollo biopsie prostatiche fase 2
Protocollo  biopsie prostatiche fase 2Protocollo  biopsie prostatiche fase 2
Protocollo biopsie prostatiche fase 2Valentina Corona
 

More from Valentina Corona (20)

Walter Artibani
Walter ArtibaniWalter Artibani
Walter Artibani
 
Progetto strategico SIU Oltre
Progetto strategico SIU OltreProgetto strategico SIU Oltre
Progetto strategico SIU Oltre
 
Telehealth in Urology: A Systematic Review of the Literature.
Telehealth in Urology: A Systematic Review of the Literature.Telehealth in Urology: A Systematic Review of the Literature.
Telehealth in Urology: A Systematic Review of the Literature.
 
Remdesivir for the Treatment of Covid-19
Remdesivir for the Treatment of Covid-19Remdesivir for the Treatment of Covid-19
Remdesivir for the Treatment of Covid-19
 
Avoidng disruption of timely surgical management of genitourinary cancers ...
Avoidng disruption of timely surgical management of genitourinary cancers ...Avoidng disruption of timely surgical management of genitourinary cancers ...
Avoidng disruption of timely surgical management of genitourinary cancers ...
 
Avoiding disruption of surgical treatment of genitourinary cancers...
Avoiding disruption of surgical treatment of genitourinary cancers...Avoiding disruption of surgical treatment of genitourinary cancers...
Avoiding disruption of surgical treatment of genitourinary cancers...
 
A systematic review on COVID-1: urological manifestations...
A systematic review on COVID-1: urological manifestations...A systematic review on COVID-1: urological manifestations...
A systematic review on COVID-1: urological manifestations...
 
Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...
Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...
Urology in the time of Coronavirus: Reduced Acmes to Urgent and Emergent Care...
 
Research Correspondence
Research CorrespondenceResearch Correspondence
Research Correspondence
 
Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...
Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...
Accessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Pr...
 
A Global Survey on the Impact of COVID-19 on Urological Services
A Global Survey on the Impact of COVID-19 on Urological ServicesA Global Survey on the Impact of COVID-19 on Urological Services
A Global Survey on the Impact of COVID-19 on Urological Services
 
Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...
 
Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...Since January Elsevier has created a COVID-19 resource center with...
Since January Elsevier has created a COVID-19 resource center with...
 
Androgen-deprivation therapies for prostate cancer and risk of infection by S...
Androgen-deprivation therapies for prostate cancer and risk of infection by S...Androgen-deprivation therapies for prostate cancer and risk of infection by S...
Androgen-deprivation therapies for prostate cancer and risk of infection by S...
 
Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces
Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on SurfacesSimulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces
Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces
 
Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...
Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...
Hydroxychloroquine or chloroquine with or without a macrolide for treatment o...
 
Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?
Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?
Chloroquine or hydroxychloroquine for Covid-19: why might they be hazardous?
 
Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19
Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19
Pulmonary Vascular Endotheliatis Thrombosis, and Angiogenesis in Covid-19
 
Assessment of Deaths from Covid 19 and from Seasonal Influenza
Assessment of Deaths from Covid 19 and from Seasonal Influenza Assessment of Deaths from Covid 19 and from Seasonal Influenza
Assessment of Deaths from Covid 19 and from Seasonal Influenza
 
Protocollo biopsie prostatiche fase 2
Protocollo  biopsie prostatiche fase 2Protocollo  biopsie prostatiche fase 2
Protocollo biopsie prostatiche fase 2
 

Recently uploaded

Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...chandars293
 
Call Girls Mumbai Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Mumbai Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...Sheetaleventcompany
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...chandars293
 
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near MeTop Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Mechennailover
 
Call Girls Varanasi Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...
Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...
Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...Dipal Arora
 
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...chennailover
 
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...karishmasinghjnh
 
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...mahaiklolahd
 
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Ishani Gupta
 
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
Kollam call girls Mallu aunty service 7877702510
Kollam call girls Mallu aunty service 7877702510Kollam call girls Mallu aunty service 7877702510
Kollam call girls Mallu aunty service 7877702510Vipesco
 
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...GENUINE ESCORT AGENCY
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In AhmedabadGENUINE ESCORT AGENCY
 
Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...adilkhan87451
 
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...parulsinha
 
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...Namrata Singh
 
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...khalifaescort01
 
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...chennailover
 

Recently uploaded (20)

Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
 
Call Girls Mumbai Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Mumbai Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Mumbai Just Call 8250077686 Top Class Call Girl Service Available
 
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
 
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near MeTop Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
Top Rated Call Girls Kerala ☎ 8250092165👄 Delivery in 20 Mins Near Me
 
Call Girls Varanasi Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 8250077686 Top Class Call Girl Service Available
 
Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...
Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...
Top Rated Pune Call Girls (DIPAL) ⟟ 8250077686 ⟟ Call Me For Genuine Sex Serv...
 
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
Coimbatore Call Girls in Thudiyalur : 7427069034 High Profile Model Escorts |...
 
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
 
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
 
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
 
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Rishikesh Just Call 8250077686 Top Class Call Girl Service Available
 
Kollam call girls Mallu aunty service 7877702510
Kollam call girls Mallu aunty service 7877702510Kollam call girls Mallu aunty service 7877702510
Kollam call girls Mallu aunty service 7877702510
 
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
 
Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service Avai...
 
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
 
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Call Girls Kolkata Kalikapur 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
 
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
Call Girls Service Jaipur {9521753030 } ❤️VVIP BHAWNA Call Girl in Jaipur Raj...
 
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
 

Presynmptoms SARS-Cov-2 Infection and Transmission in Skilled Nursing Facility

  • 1. The new engl and jour nal of medicine n engl j med  nejm.org 1 The authors’ full names, academic de- grees, and affiliations are listed in the Ap- pendix. Address reprint requests to Dr. Jernigan at the Centers for Disease Con- trol and Prevention, 1600 Clifton Rd., Mailstop A-31, Atlanta, GA 30333, or at ­jqj9@​­cdc​.­gov. *A complete list of the investigators is in- cluded in the Supplementary Appendix, available at NEJM.org. Ms. Arons and Ms. Hatfield contributed equally to this article. This article was published on April 24, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2008457 Copyright © 2020 Massachusetts Medical Society. BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can spread rapidly within skilled nursing facilities. After identification of a case of Covid-19 in a skilled nursing facility, we assessed transmission and evaluated the adequacy of symptom-based screening to identify infections in residents. METHODS We conducted two serial point-prevalence surveys, 1 week apart, in which assenting residents of the facility underwent nasopharyngeal and oropharyngeal testing for SARS-CoV-2, including real-time reverse-transcriptase polymerase chain reaction (rRT-PCR), viral culture, and sequencing. Symptoms that had been present during the preceding 14 days were recorded. Asymptomatic residents who tested positive were reassessed 7 days later. Residents with SARS-CoV-2 infection were catego- rized as symptomatic with typical symptoms (fever, cough, or shortness of breath), symptomatic with only atypical symptoms, presymptomatic, or asymptomatic. RESULTS Twenty-three days after the first positive test result in a resident at this skilled nurs- ing facility, 57 of 89 residents (64%) tested positive for SARS-CoV-2. Among 76 resi- dents who participated in point-prevalence surveys, 48 (63%) tested positive. Of these 48 residents, 27 (56%) were asymptomatic at the time of testing; 24 subsequently developed symptoms (median time to onset, 4 days). Samples from these 24 pre- symptomatic residents had a median rRT-PCR cycle threshold value of 23.1, and viable virus was recovered from 17 residents. As of April 3, of the 57 residents with SARS-CoV-2 infection, 11 had been hospitalized (3 in the intensive care unit) and 15 had died (mortality, 26%). Of the 34 residents whose specimens were sequenced, 27 (79%) had sequences that fit into two clusters with a difference of one nucleotide. CONCLUSIONS Rapid and widespread transmission of SARS-CoV-2 was demonstrated in this skilled nursing facility. More than half of residents with positive test results were asymp- tomatic at the time of testing and most likely contributed to transmission. Infec- tion-control strategies focused solely on symptomatic residents were not sufficient to prevent transmission after SARS-CoV-2 introduction into this facility. ABSTR ACT Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility M.M. Arons, K.M. Hatfield, S.C. Reddy, A. Kimball, A. James, J.R. Jacobs, J. Taylor, K. Spicer, A.C. Bardossy, L.P. Oakley, S. Tanwar, J.W. Dyal, J. Harney, Z. Chisty, J.M. Bell, M. Methner, P. Paul, C.M. Carlson, H.P. McLaughlin, N. Thornburg, S. Tong, A. Tamin, Y. Tao, A. Uehara, J. Harcourt, S. Clark, C. Brostrom‑Smith, L.C. Page, M. Kay, J. Lewis, P. Montgomery, N.D. Stone, T.A. Clark, M.A. Honein, J.S. Duchin, and J.A. Jernigan, for the Public Health–Seattle and King County and CDC COVID-19 Investigation Team*​​ Original Article The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 2. n engl j med  nejm.org2 The new engl and jour nal of medicine T he first reported case of coronavi- rus disease 2019 (Covid-19) in the United States was diagnosed in a resident of Sno- homish County, Washington, on January 20, 2020.1 In late February, an outbreak was identified in a skilled nursing facility in neighboring King Coun- ty; morbidity and mortality among residents were high, straining the regional health care system.2,3 We report another outbreak of Covid-19 in a separate skilled nursing facility in the same county. In the course of this outbreak investigation, Pub- lic Health–Seattle and King County (PHSKC) and the Centers for Disease Control and Prevention (CDC) identified residents with asymptomatic SARS-CoV-2 infection, which prompted further investigation. We performed serial point-preva- lence surveys to assess the extent of transmission and to evaluate the adequacy of symptom-based screening of residents to identify infections. Ini- tial findings of this investigation were previously reported.4 Description of the Outbreak On February 29, 2020, in response to increased local awareness of Covid-19 in King County, Washington, administrative leadership at Facility A instituted enhanced infection-control measures. Nursing staff assessed residents twice daily for possible signs and symptoms of Covid-19, includ- ing fever (oral or temporal temperature mea- surement), cough, shortness of breath, and other symptoms. Health care personnel were assessed at the start of each shift with oral temperature measurement and screening for symptoms, in- cluding cough, shortness of breath, sore throat, or any other respiratory symptoms. On March 1, one member of the health care staff tested positive for SARS-CoV-2 after having worked in a single unit (Unit 1) while symptom- atic on February 26, the first day of symptoms, and on February 28. On March 5, the facility was informed that a hospitalized resident of Unit 1 (in whom symptoms had developed on March 2 and testing was done on March 3) had been di- agnosed with Covid-19. Subsequently, all visitors were restricted and communal activities were can- celed. PHSKC and the CDC initiated an outbreak investigation, and on March 6, provided on-site infection prevention and control recommenda- tions, including the recommendation that all health care staff entering symptomatic residents’ rooms wear eye protection, a gown, gloves, and a face mask (N95 respirators were not routinely available).5 On March 8, the CDC and PHSKC offered testing to all residents in Unit 1; 13 of 15 residents present were tested for SARS-CoV-2 (2 residents declined). A total of 6 residents tested positive; of these, 4 had symptoms (e.g., fever, cough, shortness of breath, or sore throat) and 2 had been asymptomatic during the preceding 14 days. On March 9, the facility implemented Covid-19 transmission-based precautions for all residents of Unit 1, regardless of symptoms or infection status. Methods Study Population Facility A is a 116-bed skilled nursing facility di- vided into four separate units with an equal mix of short- and long-term residents in each unit. There were 89 residents present at Facility A on March 3, the date of the first positive test in a resident. Facil- ity A provided a list of full-time health care person- nel by occupation. Results of positive SARS-CoV-2 tests obtained during postmortem examination or by outside health care providers during clinical evaluation of symptomatic residents and staff were provided to the CDC and PHSKC through March 26. All symptomatic health care personnel were advised to be tested by their health care provider; asymptomatic staff members were not tested as part of this investigation. Point-Prevalence Surveys On two occasions, residents in the facility were offered SARS-CoV-2 testing as part of a facility- wide point-prevalence survey. The first survey was performed for all assenting residents, including those who had previously tested positive, on March 13 (10 days after the first resident had tested positive for SARS-CoV-2). Nasopharyngeal and oropharyngeal swabs were collected in accordance with CDC guidelines.6 A second survey was con- ducted 7 days later (March 19–20) for residents who had had either a negative test result or a positive result with atypical or no symptoms re- ported in the first survey. Symptom Assessment On the day of point-prevalence surveys, a standard- ized symptom-assessment form was completed by nurses for each resident tested. Symptoms pres- The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 3. n engl j med  nejm.org 3 Presymptomatic SARS-CoV-2 in a Nursing Facility ent during the preceding 14 days were recorded on the basis of interview and review of medical re- cords. Asymptomatic residents with a positive test result were reassessed for symptoms 7 days later. For additional details on symptom assessment, see the Supplementary Appendix, available with the full text of this article at NEJM.org. Residents were classified as symptomatic if they had had at least one new or worsened typi- cal or atypical symptom of Covid-19 in the pre- ceding 14 days. Residents with subjective fever or temperature greater than 100.0°F (37.8°C), cough, or shortness of breath were classified as symptomatic with typical symptoms.7 Residents were classified as symptomatic with atypical symp- toms if their symptoms included only chills, mal- aise, increased confusion, rhinorrhea, nasal con- gestion, sore throat, myalgia, dizziness, headache, nausea, or diarrhea. Asymptomatic residents were those who had no symptoms or only stable chronic symptoms (e.g., chronic cough without worsening). Pres- ymptomatic residents were those who were as- ymptomatic at the time of testing but developed symptoms within 7 days after testing. Residents who did not develop symptoms in the 7 days after testing remained classified as asymptomatic. Laboratory Testing The Washington State Public Health Laboratory performed one-step real-time reverse transcrip- tase–polymerase chain reaction (rRT-PCR) on all samples, using the SARS-CoV-2 CDC assay pro- tocol; cycle threshold (Ct) values were reported for two genetic markers: the N1 and N2 viral nucleocapsid protein gene regions.8,9 Values below 40 cycles indicate a positive result for SARS-CoV-2. All rRT-PCR–positive specimens from point- prevalence surveys were shipped to the CDC for viral culture using Vero-CCL-81 cells. Cells show- ing cytopathic effect were used for SARS-CoV-2 rRT-PCR to confirm isolation and viral growth in culture. Nucleic acid was extracted from rRT-PCR– positive specimens and amplified for subsequent sequencing (Oxford Nanopore MinION), with phy- logenetic trees inferred with the neighbor-joining method.10 Additional details on culture and se- quencing methods are provided in the Supplemen- tary Appendix. Analyses The daily proportions of residents with any known positive test for SARS-CoV-2 (including those tested as part of clinical management) were described according to their unit in the facility. The daily growth rate for the facility was estimated through regression analysis, using the log-transformed daily cumulative counts of all residents who were positive for SARS-CoV-2 from March 3 through March 20; doubling time was estimated by divid- ing the natural logarithm of 2 by the growth rate. Similarly, doubling time was estimated for all residents of King County, using case count data reported through the PHSKC Covid-19 data dashboard.11 All analyses were completed with SAS soft- ware, version 9.4 (SAS Institute). Data were collected as part of public health response and were deemed non–human subjects research by the CDC. Results Residents Of the 89 residents who lived in Facility A when the first resident with confirmed Covid-19 was tested, 57 (64%) had tested positive for SARS- CoV-2 either during the point-prevalence surveys, clinical evaluation, or postmortem examination as of March 26. Seventy-six residents participat- ed in the first point-prevalence survey on March 13 (Fig. 1). Of these 76 residents, 48 (63%) tested positive in either the initial or subsequent point- prevalence surveys. Demographic characteristics, coexisting conditions, and symptoms of surveyed residents were similar, regardless of test result (Table 1). Of the 48 residents who tested positive from the surveys, 17 (35%) reported typical symptoms, 4 (8%) reported only atypical symptoms, and 27 (56%) reported no new symptoms or changes in chronic symptoms at the time of testing (Table 1 and Table S1). Among the 27 residents classified as asymptomatic, 15 reported no symptoms and 12 reported only stable chronic symptoms. Fif- teen (56%) residents who were asymptomatic at the time of testing had documented cognitive impairment; similar proportions were reported in symptomatic residents (Table S2). In the 7 days after their positive test, 24 of the 27 asymptomatic residents (89%) had onset of symptoms and were recategorized as presymp- tomatic. The median time to symptom onset was 4 days (interquartile range, 3 to 5). The most com- mon new symptoms were fever (71%), cough (54%), and malaise (42%) (Table S3). The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 4. n engl j med  nejm.org4 The new engl and jour nal of medicine 76WeretestedonMarch13 89ResidentsofFacilityAonMarch3 6Werehospitalized(alltestedpositiveforSARS-CoV-2inhospital) 1Wasdischargedhome 23Werepositive 1Whopreviouslytested positivewasnegative 1Hadtypicalsymptoms 52Werenegative 49Wereretested March19–20 12Wereasymp- tomatic 9Hadtypical symptoms 2Hadatypical symptoms 15Wereasymp- tomatic 7Hadtypical symptoms 2Wereasymp- tomatic 13Werepre- symptomatic 2Hadatypical symptoms 1Wasasymp- tomatic 11Werepre- symptomatic 24Werepositive25Werenegative 82ResidentsonMarch13 2Werehospitalizedbeforetesting(bothwerefoundtobepositive duringhospitalization) 1Didnothavedataavailable 3Declinedtobetested(1foundtobepositivepostmortem) 3Leftfacilitybefore March19 The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 5. n engl j med  nejm.org 5 Presymptomatic SARS-CoV-2 in a Nursing Facility Cycle Threshold and Viral Culture rRT-PCR Ct values for the N1 genetic markers for 47 residents ranged from 13.7 to 37.9; median Ct values for the four symptom status groups were similar (asymptomatic residents, 25.5; presymp- tomatic residents, 23.1; residents with atypical symptoms, 24.2; and residents with typical symp- toms, 24.8) (Fig. 2). SARS-CoV-2 growth was iden- tified from 31 of 46 rRT-PCR–positive specimens (Fig. 2). Viral growth was observed for specimens obtained from 10 of 16 residents with typical symptoms, 3 of 4 with atypical symptoms, 17 of Figure 1 (facing page). Residents in Facility A on March 3 through Two Point-Prevalence Surveys. Shown are all 89 residents who lived in skilled nursing facility A from March 3, when the first resident tested positive for SARS-CoV-2. By March 13, the date of the first point-prevalence survey, 82 residents remained in the facility, and 76 were tested. By the second point- prevalence survey, 48 of the 76 residents tested in the point-prevalence surveys had been identified as posi- tive. Overall, 57 residents were positive as of March 26. Cycle threshold values were available for 47 residents who tested positive in the point-prevalence surveys on March 13 and March 19–20. Table 1. Demographic Characteristics and Reported Symptoms in Residents of Facility A at the Time of Testing.* Characteristics SARS-CoV-2 Test Results Positive† (N = 48) Negative‡ (N = 28) Overall Positive result during initial facility-wide cohort testing — no. (%) 23 (48) — Mean age (±SD) — yr 78.6±9.5 73.8±11.5 Length of stay at Facility A <90 days before testing — no. (%) 23 (48) 14 (50) Coexisting conditions — no. (%) Any coexisting condition 47 (98) 28 (100) Chronic lung disease 18 (38) 8 (29) Diabetes 18 (38) 11 (39) Cardiovascular disease 39 (81) 17 (61) Cerebrovascular accident 19 (40) 8 (29) Renal disease 18 (38) 9 (32) Received hemodialysis 3 (6) 1 (4) Cognitive impairment 28 (58) 13 (46) Obesity 11 (23) 6 (21) Symptoms during the past 14 days — no. (%) In symptomatic residents§ 21 (44) 11 (39) At least one typical Covid-19 symptom 17 (35) 8 (29) Only atypical Covid-19 symptoms 4 (8) 3 (11) In asymptomatic residents 27 (56) 18 (64) No symptoms 15 (31) 14 (50) Only stable, chronic symptoms 12 (25) 3 (11) * Results include all residents who were present in the facility on March 13 and assented to screening. Facility-wide co- hort symptom screens and point-prevalence surveys were performed on March 13 and March 19–20, 2020. † Residents categorized as positive include those with at least one positive test from facility-wide point-prevalence sur- veys on March 13 or March 19–20 and one resident who tested negative on March 13 but tested positive before March 13. ‡ Residents categorized as negative include 3 residents who had only one negative swab on March 13 and were not re- tested. § Typical symptoms include fever, cough, and shortness of breath. Atypical symptoms include chills, malaise, sore throat, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea. The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 6. n engl j med nejm.org6 The new engl and jour nal of medicine 24 who were presymptomatic, and 1 of 3 who remained asymptomatic. We observed no correlation between Ct values and the number of days from the first evidence of typical symptoms. Ct values consistent with a high viral load were identified among residents who tested positive before typical symptom on- set (median Ct value among 26 observations, 24.0; interquartile range, 20.4 to 28.5) and those who tested positive 7 or more days after typical symptom onset (median Ct value among 8 obser- vations, 25.0; interquartile range, 21.3 to 28.2) (Fig. 3, and Fig. S1). Viable virus was isolated from specimens collected 6 days before to 9 days after the first evidence of typical symptoms. Prevalence and Transmission in the Facility We estimated the doubling time among residents to be 3.4 days (95% confidence interval [CI], 2.5 to 5.3) (Table S4). The doubling time for the sur- rounding King County was 5.5 days (95% CI, 4.8 to 6.7). As of April 3, a total of 11 of the 57 resi- dents with SARS-CoV-2 infection identified by March 26 had been admitted to the hospital (in- cluding 3 in intensive care) and 15 had died (mor- tality, 26%). The unit where presumed introduc- tion of infection took place and where the first resident with SARS-CoV-2 infection lived (Unit 1) had the highest prevalence in the facility at the end of the first point-prevalence survey. Although other units identified SARS-CoV-2 infection in residents later, their prevalence also continued to increase (Fig. 4, and Fig. S4). By the time of the first point-prevalence sur- vey, 11 of 138 full-time staff members (8%) had had a positive test for SARS-CoV-2. By March 26, Figure 2. Cycle Threshold Values and Results of Viral Culture for Residents with Positive SARS-CoV-2 Tests According to Their Symptom Status. Shown are N1 target cycle threshold values and viral culture results for 47 residents’ first positive test for SARS-CoV-2 stratified by the resident’s symptom status at the time of the test. One positive test was not assessed for culture growth. Typical symptoms include fever, cough, and shortness of breath; atypical symptoms include chills, malaise, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea. 10 15 20 25 30 35 40 Cycle Threshold Values for N1 Target Positive culture Negative culture No culture Typical Symptoms (N=16) Atypical Symptoms (N=4) Presymptomatic (N=24) Asymptomatic (N=3) Figure 3. Cycle Threshold Values Relative to First Evidence of Fever, Cough, or Shortness of Breath. Shown are N1 target cycle threshold values and viral culture results for each resident’s positive tests for SARS-CoV-2 shown by day since the first evidence of fever, cough, or shortness of breath (N=55). Dates of onset of typical symp- toms were known for 43 residents; 12 residents with two specimens that were positive for SARS-CoV-2 are also in- cluded. One positive test was not assessed for culture growth. The relationship between the first test and the sec- ond test for residents who had two positive tests is shown in Figure S2. −9 −8 −7 −6 −5 −4 −3 −2 −1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Days from First Evidence of Fever, Cough, or Shortness of Breath CycleThresholdValuesforN1Target 15 10 20 25 35 30 40 No culturePositive culture Negative culture The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 7. n engl j med nejm.org 7 Presymptomatic SARS-CoV-2 in a Nursing Facility a total of 55 of the 138 (40%) had reported symp- toms, 51 (37%) had been tested, and 26 (19%) had received a positive test result. Of the 26 staff mem- bers with positive tests, 17 were nursing staff and 9 had occupations that provided services across multiple units during their shift (therapists, en- vironmental services, dietary services). No staff members with Covid-19 were hospitalized. Thirty-nine specimens from 34 residents were sequenced. All sequences were identical or high- ly similar to sequences reported in previous analy- ses of Covid-19 cases in Washington (Fig. S3). Of the 34 residents whose specimens were sequenced, 27 (79%) had sequences that fit into two clus- ters with one nucleotide difference (Fig. S4 and Table S5). Discussion Twenty-three days after identifying the first resi- dent with SARS-CoV-2 infection, Facility A had a 64% prevalence of Covid-19 among residents, with a case fatality rate of 26% despite early adoption of infection-control measures. In addition, Covid-19 was diagnosed in 26 members of the staff (19%). These findings are strikingly similar to descrip- tions of the first Covid-19 outbreak in a U.S. skilled nursing facility, which occurred in the same county at nearly the same time.2 In the investiga- tion reported here, more than half of the residents with positive tests were asymptomatic at the time of testing. Transmission from asymptomatic resi- dents infected with SARS-CoV-2 most likely contributed to the rapid and extensive spread of infection to other residents and staff. Symptom- based infection-control strategies were not suf- ficient to prevent transmission after the intro- duction of SARS-CoV-2 into this skilled nursing facility. Although we are unable to quantify the con- tributions of asymptomatic and presymptomatic residents to transmission of SARS-CoV-2 in this facility, evidence suggests that these residents had the potential for substantial viral shedding. Figure 4. Timeline Showing Prevalence, Notable Events, and Implementation of Infection Prevention and Control Measures at Facility A. Dashed lines indicate the prevalence of Covid-19 based on test results obtained during clinical evaluation of symptomatic residents be- fore a unit-wide or facility-wide point-prevalence survey (PPS); the dotted line indicates the prevalence based on results from a unit-spe- cific point-prevalence survey; and solid lines indicate the prevalence based on results from clinical evaluation and a facility-wide point- prevalence survey. PPE denotes personal protective equipment. PercentageofResidentsPositive forSARS-CoV-2 100 80 90 70 60 40 30 10 50 20 0 Feb.25Feb.26Feb.27Feb.28Feb.29M arch 1M arch 2M arch 3M arch 4M arch 5M arch 6M arch 7M arch 8M arch 9M arch 10M arch 11M arch 12M arch 13M arch 14M arch 15M arch 16M arch 17M arch 18M arch 19M arch 20 Unit 1 Unit 2 Unit 3 Unit 4 Total Suspected introduction of SARS-CoV-2 from symptomatic health care personnel in Unit 1. Temperature and Covid-19 symptom screening implemented for all residents and staff members. Unit-wide testing in Unit 1. Covid-19–recommended PPE implemented for all of Unit 1. Notification of PPS test results. Covid-19–recom- mended PPE imple- mented in all units. Notification of first positive test result in resident. Covid-19–recommended PPE implemented for symptomatic residents. Communal events canceled and visitors restricted. Initial facility- wide point- prevalence survey. Follow-up point- prevalence survey. The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 8. n engl j med  nejm.org8 The new engl and jour nal of medicine Ct values indicating large quantities of viral RNA were identified, and viable SARS-CoV-2 was isolated from specimens of asymptomatic and presymptomatic residents. Evidence of transmis- sion from presymptomatic persons has been shown in epidemiologic investigations of SARS- CoV-2.12-14 We estimated that the doubling time in this facility was 3.4 days, which is faster than that of the surrounding community, 5.5 days. The ac- celerated doubling time was likely to have been due to inadequately controlled intrafacility trans- mission, which sequencing and spatiotemporal data suggest was the primary driver of new in- fections. Shedding of high viral titers from the respiratory tract, including shedding before the onset of symptoms, might have led to droplet and possibly aerosol transmission. Residents and staff members with undetected SARS-CoV-2 infection are likely to have contributed to transmission through interactions between and among resi- dents and staff. The contribution of indirect con- tact transmission in this outbreak is not known. However, contaminated environmental surfaces and shared medical devices could also have played a role. Most of the early transmission ap- peared to have occurred in Unit 1, where the ini- tial introduction of SARS-CoV-2 took place, sev- eral days before other units were involved. Early recognition of initial SARS-CoV-2 introduction combined with early interventions in all units might prevent spread within a facility. The CDC and PHSKC confirmed Covid-19 infection in 26 symptomatic staff members as- sociated with this skilled nursing facility as of March 26; these staff members most likely con- tributed to intrafacility transmission. A concur- rent study of King County health care personnel with Covid-19 showed that 65% worked while symptomatic and that 17% of symptomatic health care personnel initially had mild, nonspe- cific symptoms and no fever, cough, shortness of breath, or sore throat.15 The potential for viral shedding from staff members with SARS-CoV-2 infection during either the presymptomatic or the mildly symptomatic phase of the illness re- inforces current recommendations for expanded symptom screening for health care personnel and universal use of face masks for all health care staff in long-term care facilities.5 Current interventions for preventing SARS- CoV-2 transmission in health care settings rely primarily on the presence of signs and symp- toms to identify and isolate residents and staff who might have Covid-19. The data presented here suggest that sole reliance on symptom- based strategies may not be effective to prevent introduction of SARS-CoV-2 and further trans- mission in skilled nursing facilities. Impaired immune responses associated with aging and the high prevalence of underlying conditions, such as cognitive impairment and chronic cough, make it difficult to recognize early signs and symptoms of respiratory viral infections in this population.16 Studies have shown that in the el- derly, including those living in skilled nursing facilities, influenza often manifests with few or atypical symptoms, delaying diagnosis and con- tributing to transmission.17,18 Furthermore, symp- tom-based cohorting strategies could inadver- tently increase the risk of SARS-CoV-2 exposure for uninfected residents, given that typical symp- toms were common in those who tested negative. Our investigation demonstrated a poor cor- relation between symptom onset and viral shed- ding that was potentially due to the difficulty of ascertaining precise dates of symptom onset or to differences in viral shedding in this population. Studies in other populations show that SARS- CoV-2 shedding is highest early in the illness.19,20 Our investigation shows that some facility resi- dents shed virus for more than 7 days after symptom onset, a finding seen in some other populations.21 These data support current rec- ommendations preferring a test-based strategy to discontinue transmission-based precautions for residents of skilled nursing facilities.22 If a non– test-based strategy is used, these data support extending the duration of transmission-based precautions.22 Because asymptomatic or presymptomatic residents might play an important role in trans- mission in this high-risk population, additional prevention measures merit consideration, includ- ing using testing to guide the use of transmis- sion-based precautions, isolation, and cohort- ing strategies. The ability to test large numbers of residents and staff with rapid turn-around times may expedite cohorting of residents and staff in locations designated for the care of those with SARS-CoV-2 infection either in different locations within individual facilities or in separate facilities. This investigation has several limitations. First, challenges in symptom ascertainment may The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 9. n engl j med  nejm.org 9 Presymptomatic SARS-CoV-2 in a Nursing Facility have resulted in misclassification of symptom grouping for some residents. However, multiple sources of symptom data were used to minimize such misclassification. The accuracy of symptom ascertainment for this investigation is likely to be equivalent to, if not exceed, symptom screen- ing in most skilled nursing facilities, and thus, these findings should be generalizable to this set- ting. Second, because this analysis was conducted among residents of a skilled nursing facility, it is not known whether the findings apply to the general population, including younger persons, those without underlying medical conditions, or similarly aged populations in the general com- munity or in other long-term care settings. Third, asymptomatic staff members were not tested; therefore, we are unable to document their role in transmission in this facility. SARS-CoV-2 can spread rapidly after introduc- tion into skilled nursing facilities, resulting in substantial morbidity and mortality and increas- ing the burden on regional health care systems. Unrecognized asymptomatic and presymptomatic infections most likely contribute to transmission in these settings. During the current Covid-19 pandemic, skilled nursing facilities and all long- term care facilities should take proactive steps to prevent introduction of SARS-CoV-2. These steps include restricting visitors and nonessential per- sonnel from entering the building, requiring universal use of face masks by all staff for source control while in the facility, and implementing strict screening of staff. Our data suggest that symptom-based strategies for identifying residents with SARS-CoV-2 are insufficient for preventing transmission in skilled nursing facilities. Once SARS-CoV-2 has been introduced, additional strate- gies should be implemented to prevent further transmission, including use of recommended per- sonal protective equipment, when available, during all resident care activities regardless of symptoms.5 Consideration should be given to test-based strate- gies for identifying residents and staff with SARS- CoV-2 infection for the purpose of excluding in- fected staff and cohorting residents, either in designated units within a facility or in a separate facility designated for residents with Covid-19. The findings and conclusion in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the facility residents; the staff of Facility A for their ongoing efforts to provide care in the face of these challenges; staff at the local and state health departments responding to this public health emergency; staff at the Washington State De- partment of Health Public Health Laboratories; CDC staff at the Emergency Operations Center; and members of the Covid-19 response teams at the local, state, and national levels for their unwavering commitment in the face of this global public health emergency. Appendix The authors’ full names and academic degrees are as follows: Melissa M. Arons, R.N., Kelly M. Hatfield, M.S.P.H., Sujan C. Reddy, M.D., Anne Kimball, M.D., Allison James, Ph.D., Jesica R. Jacobs, Ph.D., Joanne Taylor, Ph.D., Kevin Spicer, M.D., Ana C. Bardossy, M.D., Lisa P. Oakley, Ph.D., Sukarma Tanwar, M.Med., Jonathan W. Dyal, M.D., Josh Harney, M.S., Zeshan Chisty, M.P.H., Jeneita M. Bell, M.D., Mark Methner, Ph.D., Prabasaj Paul, Ph.D., Christina M. Carlson, Ph.D., Heather P. McLaughlin, Ph.D., Natalie Thornburg, Ph.D., Suxiang Tong, Ph.D., Azaibi Tamin, Ph.D., Ying Tao, Ph.D., Anna Uehara, Ph.D., Jennifer Harcourt, Ph.D., Shauna Clark, R.N., Claire Brostrom‑Smith, M.S.N., Libby C. Page, M.P.H., Meagan Kay, D.V.M., James Lewis, M.D., Patty Montgomery, M.P.H., Nimalie D. Stone, M.D., Thomas A. Clark, M.D., Margaret A. Honein, Ph.D., Jeffrey S. Duchin, M.D., and John A. Jernigan, M.D. The authors’ affiliations are as follows: the Centers for Disease Control and Prevention COVID-19 Emergency Response (M.M.A., K.M.H., S.C.R., A.K., A.J., J.R.J., J.T., K.S., A.C.B., L.P.O., S. Tanwar, J.W.D., J. Harney, Z.C., J.M.B., M.M., P.P., C.M.C., H.P.M.L., N.T., S. Tong, A.T., Y.T., A.U., J. Harcourt, N.D.S., T.A.C., M.A.H., J.A.J.), and the Epidemic Intelligence Service (M.M.A., A.K., A.J., J.T., A.C.B., L.P.O., S. Tanwar, J.W.D.) and the Laboratory Leadership Service (J.R.J., C.M.C.), Centers for Disease Control and Preven- tion — all in Atlanta; and Public Health — Seattle King County (S.C., C.B.-S., L.C.P., M.K., J.L., J.S.D.) and the University of Wash- ington, Department of Medicine (J.S.D.), Seattle, the Washington State Public Health Laboratory, Shoreline (J.S.D.), and the Washington State Department of Health, Tumwater (P.M.) — all in Washington. References 1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;​ 382:​929-36. 2. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a long- term care facility in King County, Wash- ington. N Engl J Med. DOI:​10.1056/ NEJMoa2005412. 3. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facil- ity — King County, Washington, February 27–March 9, 2020. MMWR Morb Mortal Wkly Rep 2020;​69:​339-42. 4. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS- CoV-2 infections in residents of a long-term care skilled nursing facility — King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep 2020;​69:​377-81. 5. Centers for Disease Control and Pre- vention. Preparing for COVID-19: long- term care facilities, nursing homes. 2020 (https://www​.cdc​.gov/​coronavirus/​2019 ​-­ncov/​healthcare​-­facilities/​prevent​-­spread​ -­in​-­long​-­term​-­care​-­facilities​.html). 6. Centers for Disease Control and Pre- vention. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.
  • 10. n engl j med  nejm.org10 The new engl and jour nal of medicine (COVID-19). 2020 (https://www​.cdc​.gov/​ coronavirus/​2019​-­ncov/​lab/​guidelines​ -­clinical​-­specimens​.html). 7. Centers for Disease Control and Pre- vention. Symptoms. Coronavirus 2019 (COVID-19). 2020 (https://www​.cdc​.gov/​ coronavirus/​2019​-­ncov/​symptoms​ -­testing/​symptoms​.html). 8. Centers for Disease Control and Pre- vention. Real-time RT-PCR panel for detec- tion 2019-novel coronavirus. 2020 (https:// www​.cdc​.gov/​coronavirus/​2019​-­ncov/​ downloads/​rt​-­pcr​-­panel​-­for​-­detection​ -­instructions​.pdf). 9. Centers for Disease Control and Pre- vention. 2019-Novel coronavirus (2019- nCoV) real-time rRT-PCR panel primers and probes. 2020 (https://www​.cdc​.gov/​ coronavirus/​2019​-­ncov/​downloads/​rt​-­pcr​ -­panel​-­primer​-­probes​.pdf). 10. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolu- tionary genetics analysis across comput- ing platforms. Mol Biol Evol 2018;​35:​ 1547-9. 11. Public Health — Seattle and King County. COVID-19 data dashboard: King County COVID-19 outbreak summary (https://kingcounty​.gov/​depts/​health/​ communicable​-­diseases/​disease​-­control/​ novel​-­coronavirus/​data​-­dashboard​ .aspx). 12. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2 — Singapore, January 23– March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;​69:​411-5. 13. Tong Z-D, Tang A, Li K-F, et al. Poten- tial presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis 2020;​26:​1052-4. 14. Qian G, Yang N, Ma AHY, et al. A COVID-19 transmission within a family cluster by presymptomatic infectors in China. Clin Infect Dis 2020 March 23 (Epub ahead of print). 15. Chow EJ, Schwartz NG, Tobolowsky FA, et al. Symptom screening at illness onset of health care personnel with SARS- CoV-2 infection in King County, Washing- ton. JAMA 2020 April 17 (Epub ahead of print). 16. Aw D, Silva AB, Palmer DB. Immu- nosenescence: emerging challenges for an ageing population. Immunology 2007;​ 120:​435-46. 17. Lam P-P, Coleman BL, Green K, et al. Predictors of influenza among older adults in the emergency department. BMC Infect Dis 2016;​16:​615. 18. Sayers G, Igoe D, Carr M, et al. High morbidity and mortality associated with an outbreak of influenza A(H3N2) in a psycho-geriatric facility. Epidemiol Infect 2013;​141:​357-65. 19. Zou L, Ruan F, Huang M, et al. SARS- CoV-2 viral load in upper respiratory spec- imens of infected patients. N Engl J Med 2020;​382:​1177-9. 20. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in pos- terior oropharyngeal saliva samples and serum antibody responses during infec- tion by SARS-CoV-2: an observational co- hort study. Lancet Infect Dis 2020 March 23 (Epub ahead of print). 21. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS- CoV-2 in Singapore. JAMA 2020 March 03 (Epub ahead of print). 22. Centers for Disease Control and Pre- vention. Discontinuation of transmission- based precautions and disposition of pa- tients with COVID-19 in healthcare settings (interim guidance). 2020 (https:// www​.cdc​.gov/​coronavirus/​2019​-­ncov/​hcp/​ disposition​-­hospitalized​-­patients​.html). Copyright © 2020 Massachusetts Medical Society. The New England Journal of Medicine Downloaded from nejm.org by ROD STER on April 24, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.